

# The Exploding World of Intravascular Imaging

*Gary S. Mintz, MD*

**Cardiovascular Research Foundation  
New York, NY**



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER

## *Modalities*

- FFR (or iFR)
- IVUS (with or without VH, iMAP, or IB-IVUS)
- OCT
- NIRS (with or without IVUS)
- Some combination of the above
- (ICE or TEE)

## Clinical questions

- Is this lesion flow-limiting?
  - Non-LMCA
  - LMCA
- Pre-intervention lesion assessment (ie., what is the culprit?)
- What is the likelihood of embolization during stent implantation?
- Is this “other” lesion a vulnerable plaque that is at risk for future events?
- How do I optimize acute stent results (size, length, expansion, edge coverage)?
- Is this jailed sidebranch significant?
- Why did this stent thrombose or restenose?



*Is this lesion significant?*



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER

	Abizaid AJC 1998; 82: 423-8	Nishioka JACC 1999; 33: 1870-8	Takagi. Circ. 1999; 100: 250-5	Briguori AJC 2001; 87: 136-41	Takayama CCI 2001;53:48 -55	Lee AJC 2010; 105: 1378- 84	Kang Circ CV Interv 2011; 4:65-71 (AJC, in press)	Ahn JACC CV Interv 2011;4:6 65-71	Ben-Dor Eurointervent 2011;7:225-33	Tahk ACC 2011	Koo JACC CV Interv 2011;4:8 03-11	Waksma n TCT2011 (F1RST)	Gonzalo JACC 2012;59: 1080-9
	CFR	SPECT	FFR	FFR	FFR	FFR	FFR	SPECT	FFR	FFR	FFR	FFR	FFR
N	112	70	51	52	14	94	236	170	92	110	267	204	17
% abn													
IVUS													
Ref lu (mm <sup>2</sup> )													
MLA off (r													4
C-st (AUC													63)
Other determ ischen													
QCA													
Length (mm)			14	8.5	17.9	15.1		21.2			16.5	15.0	7.1
QCA Ref (mm)			3.0	3.1	2.9	2.7		3.3			3.1	2.9	2.6
DS (%)			46	52	53			55			50	45	51

**All of these studies had two things in common. Lesions with an MLA above the cut-off were associated with a very low frequency of ischemia such that the negative predictive value was high, but the positive predictive value was low and c-statistic was relatively weak. Therefore, when confronted by an intermediate non-LMCA lesion in the cath lab, current evidence indicates that FFR is a better technique than IVUS.**




# IVUS vs FFR in LMCA Disease


- There is more agreement between IVUS and FFR in assessing LMCA than in assessing non-LMCA lesions
  - Limited variability in LMCA length
  - Limited variability in amount of supplied myocardium
  - Large LMCA size
- Both have theoretical and practical limitations
  - FFR
    - Proximal LAD and/or LCX disease affects FFR of LMCA
  - IVUS
    - Especially in distal LMCA lesions, it is necessary to image from both the LAD and LCX
    - It is not possible to assess the LCX from an LAD-to-LM pullback, and it is not possible to assess the LAD from an LCX-to-LM pullback
- Treatment of LMCA disease is not just for ischemia





# IVUS determinants of LMCA FFR – I (n=55 intermediate LMCA lesions)




# Prospective application of predefined IVUS criteria for revascularization of intermediate left main coronary artery lesions: Results at 2 years from the LITRO study



# Clinical outcome of pts with vs without revascularization



## Clinical outcome of pts without revascularization according to the MLA



*In the group of 16 patients with MLA  $< 6\text{mm}^2$  who were treated medically, cardiac death-free survival to 2 years was 86% (97.7% in the deferred group;  $p=0.04$ ), and survival free of cardiac death, MI, and revascularization was 62.5% (87.3% in the deferred group;  $p=0.02$ ).*





# *What is the culprit?*



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER




## Red Thrombus

Sensitivity = 95%

Specificity = 88%

Positive predictive value = 86%

Negative predictive value = 95%





## White Thrombus



- **Red thrombus** was identified as high-backscattering protrusions inside the lumen of the artery, with signal-free shadowing in the OCT image.
- **White thrombus** was identified as low-backscattering projections in the OCT image.

# In vivo comparison of OCT and angioscopy in assessing culprit lesions in 30 AMI patients

## *Plaque rupture*




## *Plaque erosion*



***What is the likelihood of distal embolization during stent implantation?***





- *Attenuated plaques were seen in 39.6-78.0% of STEMI, 17.6% of NSTEMI, and 0% of stable angina.*
- *Attenuate plaques were associated with more fibroatheromas and a larger necrotic core (on VH-IVUS).*
- *In ACS or MI pts with attenuated plaques (1) the level of CRP was higher, (2) angiographic thrombus and initial coronary flow <TIMI 2 were more common, and (3) no-reflow or flow deterioration post-PCI was also more common.*
- *In STEMI patients with attenuated plaques, the amount, not the presence, of attenuated plaque predicted no-reflow post stent implantation*
- *Attenuated plaques contained the highest NIRS probability of lipid core, and by VH-IVUS, 93.5% of attenuated plaques contained confluent necrotic core and were classified as fibroatheromas*
- *Attenuated plaque was associated with the presence of TCFA, ruptured plaques, thrombus, and greater lipid content*

(Lee et al. JACC Cardiovasc Interv. 2009;2:65-72)

(Wu et al, Am J Cardiol 2010;105:48-53)

(Okura et al, Circ J 2007;71:648-53)


(Wu et al. JACC Cardiovasc Interv 2011;4:495-502)

(Pu et al. Eur Heart J, in press)

(Lee et al JACC Cardiovasc Interv. 2011;4:483-91)

(Kubo et al. Cardiol Res Pract. 2011;687515)

# VH-IVUS and Peri-procedural MI



- Kawamoto (n=44) 2007: NC was an independent predictor of the tertile with the greatest # of HITS
- Bose (n=55) 2008: Strong correlations between NC and the maximum increase in cardiac biomarkers
- Yamada (n=30) 2010: IMR improved post-PCI in the non-VH-TCFA group, but worsened in the VH-TCFA group
- Hong (n=190) 2011:  $\geq 1$  VH-TCFA or multiple VH-TCFAs more common in no-reflow

# OCT and peri-procedural MI

- **OCT-TCFAs** were more common in the no-reflow group than in the normal reflow group (50% vs. 16%,  $P=0.005$ ). The frequency of no-reflow and deterioration of final TIMI blush increased according to the arc of lipid
  - Tanaka et al. Eur Heart J 2009;30:1348-55
- Independent predictors of post-PCI MI (cTnl  $>3x$  ULN) were **OCT-TCFA** (OR=10.47,  $p<0.001$ ), type B2/C lesions (OR=3.74,  $p=0.008$ )
  - Lee et al. Circ Cardiol Intv 2011;4:378-86
- Independent predictors of post-PCI CK-MB elevation were attenuated plaque (OR=3.49,  $p=0.003$ ) and **OCT ruptured plaque** (OR=2.92,  $p=0.017$ )
  - Lee et al. J Am Coll Cardiol Intv 2011;4:483-91
- Independent predictors of post-PCI TnT elevation were **OCT-TCFA** (OR 29.7), intrastent thrombus (OR 5.5), and intrastent dissection (OR 5.3)
  - Porto et al. Circ Cardiovasc Intv 2012;5:89-96







# COLOR Registry

- 62 patients undergoing stenting were studied pre-PCI using NIRS
  - Peri-procedure MI (cTnl >3x normal) occurred in 9 patients
  - Predictors:

	RR	95% CI	p
maxLCBI <sub>4mm</sub> >500	12.0	3.3-48	0.0002
LDL >100mg/dL	5.4	1.4-23	0.03
Angiographic complex plaque	3.5	0.91-14	0.15
Angiographic DS >75%	3.1	0.92-11	0.14





# Low probability of distal embolization predictable by absence of

- Attenuated plaque – grayscale IVUS
- VH-TCFA or large necrotic core
- OCT-TCFA or plaque rupture
- Large lipid core plaque - NIRS



***Is this “other” lesion a  
vulnerable plaque?***



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER

# **PROSPECT: Multivariable Correlates of Non Culprit Lesion Related Events**


Independent predictors of lesion level events by Cox Proportional Hazards regression

Variable	HR [95% CI]	p
$PB_{MLA} \geq 70\%$	5.03 [2.51, 10.11]	<0.0001
VH-TCFA	3.35 [1.77, 6.36]	0.0002
$MLA \leq 4.0 \text{ mm}^2$	3.21 [1.61, 6.42]	0.001


Variables entered into the model: minimal luminal area (MLA)  $\leq 4.0 \text{ mm}^2$ ; plaque burden at the MLA ( $PB_{MLA} \geq 70\%$ ); external elastic membrane at the MLA ( $EEM_{MLA} < \text{median} (14.1 \text{ mm}^2)$ ); lesion length  $\geq \text{median} (11.2 \text{ mm})$ ; distance from ostium to MLA  $\geq \text{median} (30.4 \text{ mm})$ ; remodeling index  $\geq \text{median} (0.94)$ ; VH-TCFA.



# PROSPECT: Predictors of Non Culprit Lesion Events



# Non Fibroatheromas and Non Culprit Lesion Events



Lesion HR	0.22 [0.10, 0.49]	1.49 [0.44, 3.39]	1.25 [0.17, 9.01]	2.60 [0.36, 18.84]
P-value	0.0002	0.70	0.83	0.34
Prevalence	67.9%	19.7%	5.6%	2.7%

# **VIVA: Virtual Histology in Vulnerable Atherosclerosis**

- **932 non-culprit lesions in 170 pts were identified with 3-vessel IVUS imaging**
- **At a median follow-up of 625 days, there were 18 culprit and non-culprit MACE in 16 pts**
  - **14 revascularizations, 2 MIs, and 2 deaths**
- **Univariate predictors of non-culprit MACE**
  - **Non-calcified VH-TCFA ( $p=0.025$ )**
    - **MLA  $<4\text{mm}^2$  ( $p=0.021$ )**
  - **Plaque burden  $>70\%$  ( $p<0.001$ )**
  - **Remodeling index ( $p=0.014$ )**

# OCT findings and lesion progression

	Progression*	No Progression	P-value	OR	P-value
Plaque rupture	61.5%	8.9%	<0.01	10.2	<0.001
Microchannels	76.9%	14.3%	<0.01	20.0	<0.001
Lipid pools	100%	60.7%	0.02	2.16	0.2
TCFA	76.9%	14.3%	<0.01	20.0	<0.001
Macrophages	61.5%	14.3%	<0.01	9.0	0.001
Thrombus	30.8%	1.8%	<0.01	12.0	0.002

*\*decrease in QCA  
MLD >0.4mm*

*Univariate analysis showed that **OCT-TCFA** and **microchannels** (both OR=20.0, p<0.01) correlated with progression*



# *How do I optimize acute stent results?*



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER

# IVUS Predictors of BMS Thrombosis & Restenosis


	Thrombosis	Restenosis
<b>Small MSA or underexpansion</b>	<ul style="list-style-type: none"> <li>• <i>Cheneau et al. Circulation 2003;108:43-7</i></li> </ul>	<ul style="list-style-type: none"> <li>• <i>Kasaoka et al. J Am Coll Cardiol 1998;32:1630-5</i></li> <li>• <i>Castagna et al. AHJ 2001;142:970-4</i></li> <li>• <i>de Feyter et al. Circulation 1999;100:1777-83</i></li> <li>• <i>Sonoda et al. J Am Coll Cardiol 2004;43:1959-63</i></li> <li>• <i>Morino et al. Am J Cardiol 2001;88:301-3</i></li> <li>• <i>Ziada et al. Am Heart J 2001;141:823-31</i></li> <li>• <i>Doi et al. JACC Cardiovasc Interv. 2009;2:1269-75</i></li> </ul>
<b>Edge problems (geographic miss, secondary lesions, large plaque burden, dissections, etc)</b>	<ul style="list-style-type: none"> <li>• <i>Cheneau et al. Circulation 2003;108:43-7</i></li> </ul>	<ul style="list-style-type: none"> <li>• <i>Sakurai et al. Am J Cardiol 2005;96:1251-3</i></li> <li>• <i>Liu et al. Am J Cardiol 2009;103:501-6</i></li> </ul>
<b>Stent length</b>		<ul style="list-style-type: none"> <li>• <i>Kasaoka et al. J Am Coll Cardiol 1998;32:1630-5</i></li> <li>• <i>de Feyter et al. Circulation 1999;100:1777-83</i></li> </ul>



# Meta-analysis of Randomized Trials of IVUS vs Angiographic Guided BMS implantation (n=2193 pts)

*IVUS guidance was associated with significantly lower rate of*

- *Angiographic restenosis (22.2% vs. 28.9%; OR 0.64, p=0.02)*
  - *Repeat revascularization (12.6% vs. 18.4%; OR 0.66, p=0.004)*
  - *Overall MACE (19.1% vs. 23.1%; OR 0.69, p=0.03)*
- but no significant effect on MI (p=0.51) or mortality (p=0.18).*



# IVUS Predictors of DES Thrombosis & Restenosis

	Thrombosis	Restenosis
<b>Small MSA or MLA or underexpansion</b>	<ul style="list-style-type: none"> <li>• Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8)</li> <li>• Okabe et al., <i>Am J Cardiol.</i> 2007;100:615-20</li> <li>• Liu et al. <i>JACC Cardiovasc Interv.</i> 2009;2:428-34</li> <li>• Choi et al. <i>Circulation Cardiovasc Interv.</i> 20011;4:239-47</li> </ul>	<ul style="list-style-type: none"> <li>• Sonoda et al. <i>J Am Coll Cardiol</i> 2004;43:1959-63</li> <li>• Hong et al. <i>Eur Heart J</i> 2006;27:1305-10</li> <li>• Doi et al <i>JACC Cardiovasc Interv.</i> 2009;2:1269-75</li> <li>• Fujii et al. <i>Circulation</i> 2004;109:1085-1088</li> <li>• Hahn et al. <i>J Am Coll Cardiol</i> 2009;54:110-7</li> <li>• Kang et al. <i>Circ Cardiovasc Interv</i> 2011;4:9-14</li> <li>• Kang et al. <i>Circ Cardiovasc Interv</i> 2011;4:562-9</li> <li>• Choi et al. <i>Am J Cardiol</i> 2012;109:455-60</li> </ul>
<b>Edge problems (geographic miss, secondary lesions, large plaque burden, dissections, etc)</b>	<ul style="list-style-type: none"> <li>• Fujii et al. <i>J Am Coll Cardiol</i> 2005;45:995-8</li> <li>• Okabe et al., <i>Am J Cardiol.</i> 2007;100:615-20</li> <li>• Liu et al. <i>JACC Cardiovasc Interv.</i> 2009;2:428-34</li> <li>• Choi et al. <i>Circulation Cardiovasc Interv.</i> 20011;4:239-47</li> </ul>	<ul style="list-style-type: none"> <li>• Sakurai et al. <i>Am J Cardiol</i> 2005;96:1251-3</li> <li>• Liu et al. <i>Am J Cardiol</i> 2009;103:501-6</li> <li>• Costa et al, <i>Am J Cardiol,</i> 2008;101:1704-11</li> </ul>



# The following 8 registries have reported the advantages of IVUS-guided DES implantation

- *Roy et al. Eur Heart J 2008;29:1851-7*
  - Unselected pts, propensity score matching (n=884 in each group)
- *Costantini. TCT 2008*
  - Unselected pts (n=952 / n=398)
- *Park et al. Circ Cardiovasc Intervent 2009;2:167-77*
  - LMCA pts, propensity score matching (n=145 in each group)
- *Kim et al. Am Heart J 2011;161:180-7*
  - Bifurcation lesions, propensity score matching (n=487 in each group)
- *Claessen et al. JACC Cardiovasc Interv 2011;4:974-81*
  - Unselected pts, propensity score matching (n=584 in each group)
- *Kim et al. Am J Cardiol 2010;106:612-8*
  - Bifurcation lesions, propensity score matching (n=303 / n=111)
- *Patel et al. Am J Cardiol, in press*
  - Bifurcation lesions, propensity score matching (n=247 / n=202)
- *Hur et al. Catheter Cardiovasc Intervent, in press*
  - Unselected pts, propensity score matching and and adjustment for inverse-probability-of-treatment weighting (n=2765/ / n=1816)



# Conversely, the following two studies did not reported an advantage to IVUS guided DES implantation in the setting of an AMI

- ***Maluenda et al. Catheter Cardiovasc Interv. 2010 ;75:86-92***
  - Clinical outcomes of 382 pts who underwent IVUS-guided PCI were compared to 523 pts who did not. Patients with cardiogenic shock and rescue PCI were excluded. The overall rates of the composite of 1-yr death, MI, and TLR were similar (14.5% vs. 14.3%,  $p=0.9$ ) as were the rates of definite and probable stent thrombosis at 1 year (2.1% vs. 2.1%,  $p=1.0$ ) in the IVUS-guided and no-IVUS groups, respectively. After multivariate and propensity score adjustment, IVUS guidance was not an independent predictor for the primary endpoint.
- ***Ahmed et al. Am J Cardiol. 2011;108:8-14***
  - Employing data from Korea Acute Myocardial Infarction Registry (KAMIR and excluding pts with cardiogenic shock and rescue PCI after thrombolysis, clinical outcomes of 2,127 pts who underwent IVUS-guided PCI were compared to 8,235 patients who did not. After multivariate analysis and propensity score adjustment, there was only a trend for IVUS guidance to predict a lower 12-month all-cause mortality (hazard ratio 0.212, 0.026 to 1.73,  $p=0.148$ )



# Randomized comparison of IVUS vs OCT-guided stenting with blinded cross-over imaging (n=70)

	IVUS	OCT	P-value
Imaging success	94.3%	9.1%	<0.0001
Use of distal protection	2.9%	22.9%	0.03
Final inflation pressure, atm	16.1 ± 4.7	13.5 ± 3.4	0.03
Final balloon diameter, mm	3.2 ± 0.4	3.4 ± 0.6	0.3
Proximal edge			
Plaque burden, %	37.1 ± 10.1	45.7 ± 10.9	0.001
Plaque burden >50%	8.6%	31.4%	0.04
MSA, mm <sup>2</sup>	7.1 ± 2.1	6.1 ± 2.2	0.04
Focal expansion	80 ± 13%	65 ± 14%	0.001
Distal edge			
Plaque burden, %	33.3 ± 6.4	40.3 ± 8.8	<0.001
Plaque burden >50%	2.9%	11.4%	0.4

*All OCT findings including the frequency of stent malapposition and the percentage of cross sections with malapposed strute were not significantly different between the groups.*

***Is this jailed sidebranch  
significant?***







CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER





# FFR Assessment of Jailed Sidebranches

- Koo et al, J Am Coll Cardiol 2005;46:633-7 (n=97 non-LMCA bifurcations)
  - Optimal cutoff value for DS to predict FFR <0.75 was 85% (AUC of 0.85)
  - Only 27% of lesions with DS >75% had FFR <0.75.
  - At a mean follow-up of 9.6 months, in patients with an FFR >0.75, there were no adverse events or target vessel revascularizations.
- Nam et al, Korean Circ J. 2011;41:304-7 (n=29 distal LMCA bifurcations)
  - No lesion with  $\leq 50$  %DS of the LCX ostium had FFR <0.80, 5/17 lesions with >50 %DS had FFR <0.80, 3/8 lesions with >70 %DS had FFR <0.80.
  - The best cut-off value to predict FFR <0.80 was angiographic DS > was 82%
- Ahn et al, JACC Cardiovasc Interv 2012;5:155-61 (n=230, 206 LAD/diagonal bifurcations)
  - Among 67 sidebranches with >50% DS, 19 (28.4%) had FFR  $\leq 0.80$ , and among 163 sidebranches with  $\leq 50$ %, 22 (13.5%) had FFR  $\leq 0.80$
  - The optimal cutoff value to predict FFR  $\leq 0.80$  was DS of 54.9%
  - Kissing balloon inflations were performed in 72, 46.3% of lesions with an FFR  $\leq 0.80$  and 29.6% of lesions with FFR >0.80.
  - At a median follow-up of 22.5 months, there was only 1 death and 4 TVR



# *Why did this stent thrombose or restenose?*



	Early BMS Thrombosis ( $<30$ days)	Early DES Thrombosis ( $<30$ days)	Late DES Thrombosis (30 days – 1 year)	Very Late DES Thrombosis ( $>1$ year)
Underexpansion	+	+		
Inflow/outflow problems	+	+		
Acute malapposition				
Late acquired malapposition $\pm$ positive remodeling				+
Vessel wall inflammation				+
Strut fracture				+
Lack of stent strut tissue coverage				+
Neointimal hyperplasia				+ (frequency increases with time)



# OCT and IVUS in DES with MI due to VLST

Median time to presentation 615 days (394, 1186)

	VLST	Controls*	P
Stents	18	36	
Cross-sections with uncovered struts (%)	33.3 (0, 43.7)	9 (0, 7.8)	0.003
Cross-sections with >30% uncovered struts (%)	21.6 (0, 43.7)	0 (0, 6.9)	0.002
Malapposed struts per patient (%)	5.9±6.3	1.8±1.5	0.001
Minimum stent CSA (mm <sup>2</sup> )	5.7±1.4	5.9±1.4	1.0
Mean EEM CSA (mm <sup>2</sup> )	19.4±5.8	15.1±4.6	0.003
“Remodeling index” (lesion/reference EEM CSA)	1.24 (1.06, 1.43)	0.99 (0.90, 1.11)	<0.001
Malapposition area (mm <sup>2</sup> )	4.1±2.3	1.2±1.5	0.001

Thrombus aspiration demonstrated neutrophils and eosinophils in the majority of cases.

\*matched for: stent type and IVUS reference EEM and lumen CSA and stent diameter


# Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation (n=18)

- 4 patients had ruptured and lipid-laden neointima, but no uncovered or malapposed stent struts.
- 14 patients without neointimal rupture had uncovered struts (n=9), malapposed struts (n=7), and/or lipid-laden neointima (n=4)



# Optical coherence tomography findings of very late stent thrombosis after bare metal (n=6) or drug-eluting stent implantation (n=27)


- Combining BMS and DES
  - Intimal rupture was seen in 70% of which 96% had thrombi at the rupture site
  - LSM was seen in 42%, but only 64% had thrombi at the rupture site
  - 18% had both intimal rupture and LSM; 6% had neither
- All BMS had intimal rupture with LSM
- Among 27 DES with VLST
  - 63% had intimal rupture, 52% had LSM, and 22% had both intimal rupture and LSM
  - 11% had strut fracture





# Late DES Catch-Up Among IVUS Substudy Patients

%IH volume



*\*defined as 4-9 months*



# OCT and In-stent Neointimal Proliferation after BMS - I

	<6months	>5years
#	20	21
Lipid laden intimal	0	67%
Intimal disruption	0	38%
Thrombus	5%	52%
Intraintimal neovasacularization	0%	62%

*Takano et al. J Am Coll Cardiol 2009;55:26-33*

***In 39 pts (60 BMS) who underwent OCT imaging 6.5 ± 1.3ys after BMS implantation, lipid-rich neointima was found in 20 stents (33.3%) in 16 pts (41%) with an average fibrous cap thickness of 56.7 ± 5.8µ. Six pts had plaque disruption and 6 patients had mural thrombus.***

*Hou et al. Heart. 2010;96:1187-90.*

# OCT and In-stent Neoatherosclerosis after BMS - II


	>5 years	<1 year	P-value
#	43	39	
Homogeneous neointima*	39.5±28.5%	94.2±11.5%	<0.0001
Heterogeneous neointima*	60.5%±28.5%	5.8±11.5%	<0.0001
Microvessels*			
Peri-stent	25.6±18.6%	6.8±8.6%	<0.0001
Neointima	13.1±12.8%	0	<0.0001
Disrupted neointima	18.6%	0	0.006
Intraluminal material	20.9%	2.6%	0.02
With shadowing	16.2%	0	0.01
Without shadowing	4.7%	2.6%	1.0

*\*of sections throughout the stent*

# In-stent Neointimal Hyperplasia after DES (n=50, median follow-up of 32 months)



- 52% lesions had at least one in-stent TCFA-like neointima
- 58% had at least one in-stent neointimal rupture.
- Patients presenting with unstable angina showed
  - Thinner fibrous cap ( $55\mu$  vs.  $100\mu$ ,  $p=0.006$ )
  - Higher incidence of TCFA-like neointima (75% vs. 37%,  $p=0.008$ )
  - Higher incidence of neointimal rupture (75% vs. 47%,  $p=0.044$ )
  - Higher incidence of thrombi (80% vs. 43%,  $p=0.010$ ) and red thrombi (30% vs. 3%,  $p=0.012$ )

*Survival free of  
TCFA-like neointima,  
neointimal rupture,  
or red thrombus*




# Late in-stent neoatherosclerosis in DES

Microvessel TCFA-like neointima




Calcium





Red


thrombus




Neointimal rupture




Mixed  
thrombus



White  
thrombus





- Only in the cath lab do we look for a single modality to answer all questions – the legacy of coronary angiography.
- Although cost and education continue to be hurdles, the thoughtful physician picks the right modality to answer the clinical question – just as in the rest of medical practice.

